🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 67 of 857 · Phase 3 first, then by program name

  1. FKB238 (bevacizumab)

    Centus Biotherapeutics Europe Limited

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  2. FLECAINIDE

    Pari Pharma GmbH

    Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardia

    phase 3 small molecule active

    1 trial

  3. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  4. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  5. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  6. FLUOROURACIL , CAPECITABINE , Folikabi 10 mg/ml oplossing voor injectie/infusie, OXALIPLATIN

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial

  7. FLUOROURACIL , OXALIPLATIN , GEMCITABINE , FOLIC ACID

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  8. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  9. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus Biosciences

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  10. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  11. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  12. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  13. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  14. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  15. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  16. FMX101

    Cutia Therapeutics (Shanghai) Co., Ltd

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  17. FMX103 1.5%

    VYNE Therapeutics

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial

  18. FMX103 minocycline foam 1.5%

    VYNE Therapeutics

    Facial Papulopustular Rosacea

    phase 3 small molecule completed

    2 trials

  19. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Tour Hekla

    Benign Prostate Hyperplasia

    phase 3 small molecule active

    1 trial

  20. FS MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    2 trials

  21. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  22. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  23. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  24. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources